DISEASE CHARACTERISTICS:

• Diagnosis of a hematologic malignancy of 1 of the following types:

  • Chronic lymphocytic leukemia, meeting 1 of the following criteria:

    • Relapsed after fludarabine therapy
    • No complete remission (CR) after salvage regimen

  • Hodgkin's or non-Hodgkin's lymphoma (all types, including mantle cell lymphoma and hepatosplenic gamma/delta T-cell lymphoma) or multiple myeloma, meeting 1 of the following criteria:

    • Primary treatment failure*
    • Relapsed after autologous stem cell transplantation (SCT)*
    • No CR after salvage regimen (for multiple myeloma only) NOTE: *Requirement waived for patients with hepatosplenic gamma/delta T-cell lymphoma

  • Acute myeloid leukemia*, meeting 1 of the following criteria:

    • First CR with high-risk cytogenetics (abnormalities other than t [8;21], t [15;17], or inv [16])
    • Second CR or greater

  • Acute lymphoblastic leukemia*, meeting 1 of the following criteria:

    • First CR with high-risk cytogenetics (e.g., t [4;11], t [1;19], t [8;14], t [9;22], or bcr-abl rearrangement)
    • Second CR or greater NOTE: *Patients with acute leukemia must be in hematologic remission, defined as less than 5% blasts in blood or bone marrow

OR

• Diagnosis of a myelodysplastic syndrome of 1 of the following types:

  • Refractory anemia with excess blasts (RAEB)
  • RAEB in transformation (if blasts are less than 10% in marrow and blood after induction chemotherapy) OR

• Diagnosis of a myeloproliferative disorder of 1 of the following types:

  • Idiopathic myelofibrosis
  • Polycythemia vera
  • Essential thrombocytosis
  • Chronic myelomonocytic leukemia

  • Chronic myelogenous leukemia, meeting 1 of the following criteria:

    • Chronic or accelerated phase (in patients 50 to 75 years old)
    • Not eligible for myeloablative allogeneic hematopoietic SCT (in patients 18 to 50 years old)
• No active CNS involvement

• First-degree relative matched donor available

  • Matched at 6/6 HLA antigens (A, B, and DR)

PATIENT CHARACTERISTICS:

Age

• 18 to 75

Performance status

• ECOG 0-2 OR
• Karnofsky 60-100%

Life expectancy

• At least 3 months

Hematopoietic

• See Disease Characteristics
• Absolute neutrophil count at least 1,000/mm^3*
• Platelet count at least 20,000/mm^3* (without transfusion) NOTE: Values below these levels may be acceptable at the discretion of the principal investigator if thought to be due to bone marrow involvement by the malignancy

Hepatic

• Bilirubin less than 2.5 mg/dL
• AST and ALT no greater than 2.5 times upper limit of normal* (higher levels accepted if there is liver involvement)

• No chronic active hepatitis B

  • Hepatitis B core antibody positive allowed if surface antigen negative and no evidence of active infection
• No hepatitis C infection NOTE: *If these values do not normalize during induction chemotherapy, patients will not be eligible for the transplantation phase, and thus will be taken off study

Renal

• Creatinine no greater than 1.5 mg/dL
• Creatinine clearance at least 50 mL/min

Cardiovascular

• LVEF greater than 45% by MUGA or 2-D echocardiogram

Pulmonary

• DLCO greater than 50% of expected (corrected for hemoglobin)

Other

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• HIV negative
• No active infection not responding to antimicrobial therapy
• No psychiatric disorder that would preclude study compliance or ability to give informed consent

PRIOR CONCURRENT THERAPY:

Biologic therapy

• See Disease Characteristics

Chemotherapy

• See Disease Characteristics
• At least 2 weeks since prior cytotoxic chemotherapy

Endocrine therapy

• Not specified

Radiotherapy

• Not specified

Surgery

• Not specified

Other

• At least 2 weeks since prior anticancer therapy and recovered
• No concurrent combination of trimethoprim and sulfamethoxazole (i.e., co-trimoxazole) or nonsteroidal anti-inflammatory drugs during methotrexate therapy